Roche offers to buy out Genentech

Swiss pharmaceutical group Roche says it is offering $43.7 billion (SFr44.7 billion) to take over the remaining shares of Genentech.

This content was published on July 21, 2008 - 08:54

Roche, which already owns 55.9 per cent of the San Francisco-based drug maker, said on Monday it was offering $89 per share, 8.8 per cent above the closing price on Friday and 19 per cent above the price a month ago.

"The combined entity will be the seventh-largest US pharmaceuticals company in terms of market share," Roche said in a statement.

The total offer is the largest ever made by a Swiss concern for a takeover.

Roche has been a partner with Genentech since 1990.

Also on Monday Roche revealed that its profit for the first half of the year had dropped by two per cent to SFr5.732 billion. Turnover fell by four per cent to SFr22.004 billion.

Articles in this story

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.